Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

TDP-43: a new player on the AD field?

Youmans KL, Wolozin B.

Exp Neurol. 2012 Sep;237(1):90-5. doi: 10.1016/j.expneurol.2012.05.018. Epub 2012 Jun 4. Review. No abstract available.

2.

[Frontotemporal lobar degeneration with TDP-43-positive inclusions and amyotrophic lateral sclerosis with dementia].

Kishimoto Y, Yokota O, Takeda N, Ikeda C, Arai T.

Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:384-8. Japanese. No abstract available.

PMID:
22755219
3.

Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments.

Swarup V, Phaneuf D, Bareil C, Robertson J, Rouleau GA, Kriz J, Julien JP.

Brain. 2011 Sep;134(Pt 9):2610-26. doi: 10.1093/brain/awr159. Epub 2011 Jul 13.

PMID:
21752789
4.

TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Baloh RH.

FEBS J. 2011 Oct;278(19):3539-49. doi: 10.1111/j.1742-4658.2011.08256.x. Epub 2011 Aug 24. Review.

5.

The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.

Collins M, Riascos D, Kovalik T, An J, Krupa K, Krupa K, Hood BL, Conrads TP, Renton AE, Traynor BJ, Bowser R.

Acta Neuropathol. 2012 Nov;124(5):717-32. doi: 10.1007/s00401-012-1045-x. Epub 2012 Sep 21.

6.

Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies.

Geser F, Lee VM, Trojanowski JQ.

Neuropathology. 2010 Apr;30(2):103-12. doi: 10.1111/j.1440-1789.2009.01091.x. Epub 2010 Jan 25. Review.

7.

Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid.

Bigio EH, Wu JY, Deng HX, Bit-Ivan EN, Mao Q, Ganti R, Peterson M, Siddique N, Geula C, Siddique T, Mesulam M.

Acta Neuropathol. 2013 Mar;125(3):463-5. doi: 10.1007/s00401-013-1089-6. Epub 2013 Feb 3. No abstract available.

8.

β-amyloid triggers ALS-associated TDP-43 pathology in AD models.

Herman AM, Khandelwal PJ, Stanczyk BB, Rebeck GW, Moussa CE.

Brain Res. 2011 Apr 22;1386:191-9. doi: 10.1016/j.brainres.2011.02.052. Epub 2011 Mar 2.

9.

Primary lateral sclerosis: upper-motor-predominant amyotrophic lateral sclerosis with frontotemporal lobar degeneration--immunohistochemical and biochemical analyses of TDP-43.

Kosaka T, Fu YJ, Shiga A, Ishidaira H, Tan CF, Tani T, Koike R, Onodera O, Nishizawa M, Kakita A, Takahashi H.

Neuropathology. 2012 Aug;32(4):373-84. doi: 10.1111/j.1440-1789.2011.01271.x. Epub 2011 Nov 21.

PMID:
22098653
10.

Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Riku Y, Watanabe H, Yoshida M, Tatsumi S, Mimuro M, Iwasaki Y, Katsuno M, Iguchi Y, Masuda M, Senda J, Ishigaki S, Udagawa T, Sobue G.

JAMA Neurol. 2014 Feb;71(2):172-9. doi: 10.1001/jamaneurol.2013.5489.

PMID:
24378564
11.

The role of mutant TAR DNA-binding protein 43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Janssens J, Kleinberger G, Wils H, Van Broeckhoven C.

Biochem Soc Trans. 2011 Aug;39(4):954-9. doi: 10.1042/BST0390954. Review.

PMID:
21787329
12.

Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion.

Bieniek KF, Murray ME, Rutherford NJ, Castanedes-Casey M, DeJesus-Hernandez M, Liesinger AM, Baker MC, Boylan KB, Rademakers R, Dickson DW.

Acta Neuropathol. 2013 Feb;125(2):289-302. doi: 10.1007/s00401-012-1048-7. Epub 2012 Sep 28.

13.

TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Lagier-Tourenne C, Polymenidou M, Cleveland DW.

Hum Mol Genet. 2010 Apr 15;19(R1):R46-64. doi: 10.1093/hmg/ddq137. Epub 2010 Apr 15. Review.

14.

The frontotemporal syndromes of ALS. Clinicopathological correlates.

Strong MJ, Yang W.

J Mol Neurosci. 2011 Nov;45(3):648-55. doi: 10.1007/s12031-011-9609-0. Epub 2011 Aug 2. Review.

PMID:
21809041
15.

TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.

Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH.

Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18809-14. doi: 10.1073/pnas.0908767106. Epub 2009 Oct 15.

16.

[FTLD/ALS as TDP-43 proteinopathies].

Ishihara T, Ariizumi Y, Shiga A, Yokoseki A, Sato T, Toyoshima Y, Kakita A, Takahashi H, Nishizawa M, Onodera O.

Rinsho Shinkeigaku. 2010 Nov;50(11):1022-4. Review. Japanese.

PMID:
21921552
17.

TDP-43 toxicity in yeast.

Armakola M, Hart MP, Gitler AD.

Methods. 2011 Mar;53(3):238-45. doi: 10.1016/j.ymeth.2010.11.006. Epub 2010 Nov 27. Review.

18.

TDP-43 in aging and Alzheimer's disease - a review.

Wilson AC, Dugger BN, Dickson DW, Wang DS.

Int J Clin Exp Pathol. 2011 Jan 30;4(2):147-55. Review.

19.

Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis.

Irwin DJ, McMillan CT, Brettschneider J, Libon DJ, Powers J, Rascovsky K, Toledo JB, Boller A, Bekisz J, Chandrasekaran K, Wood EM, Shaw LM, Woo JH, Cook PA, Wolk DA, Arnold SE, Van Deerlin VM, McCluskey LF, Elman L, Lee VM, Trojanowski JQ, Grossman M.

J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):163-9. doi: 10.1136/jnnp-2012-303507. Epub 2012 Oct 31.

20.

Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration.

Kadokura A, Yamazaki T, Kakuda S, Makioka K, Lemere CA, Fujita Y, Takatama M, Okamoto K.

Neurosci Lett. 2009 Sep 29;463(1):87-92. doi: 10.1016/j.neulet.2009.06.024. Epub 2009 Jun 17.

PMID:
19539703

Supplemental Content

Support Center